Evidence map›Paper›PMID 34337531›Full record

ArticleEuropean urology open science2021

Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study.

Jeffrey J Tosoian, Rodney L Dunn, Yashar S Niknafs, Anjan Saha, Randy A Vince, Jennifer L St Sauver, Debra J Jacobson, Michaela E McGree, Javed Siddiqui, Jack Groskopf and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Jeffrey J TosoianDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Rodney L DunnDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Yashar S NiknafsMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Anjan SahaMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Randy A VinceDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Jennifer L St SauverDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Debra J JacobsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Michaela E McGreeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Javed SiddiquiDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Jack GroskopfMDxHealth Inc., Irvine, CA, USA.
Steven J JacobsenDepartment of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena, CA, USA.
Scott A TomlinsDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Lakshmi P KunjuDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Simpa S SalamiDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
John T WeiDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Arul M ChinnaiyanDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Aruna V SarmaDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
University of Michigan · USMayo Clinic in Florida · USHoward Hughes Medical Institute · USKaiser Permanente · US

Funding

Interdisciplinary Infrastructure for Aging Research: Rochester Epidemiology ProjectR33AG058738 · NIA · MAYO CLINIC ROCHESTER · PI LEBRASSEUR, NATHAN K, OLSON, JANET E · 2020 to 2022
$2.4M
The Role of Centromeres in the Molecular Biology of Prostate CancerF30CA210379 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAHA, ANJAN KUMAR · 2016 to 2018
$119k
NCI NIH HHS F30 CA210379NIA NIH HHS R33 AG058738
6 · The paper itself

Abstract

backgroundSerum prostate-specific antigen (PSA), used in prostate cancer screening, is nonspecific for cancer and is affected by age and prostate volume. More specific biomarkers could be more accurate for early detection of prostate cancer and reduce unnecessary prostate biopsies.

objectiveTo evaluate the association of age and prostate volume with urinary MyProstateScore (MPS) in a screened, longitudinal cohort without evidence of prostate cancer. DESIGN SETTING AND

participantsThe Olmsted County Study included men aged 40-79 yr who underwent biennial prostate cancer screening. PSA ≥4.0 ng/ml or abnormal rectal examination triggered prostate biopsy, and patients with cancer were excluded. The remaining men submitted urinary specimens for PCA3 and TMPRSS2:ERG testing. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: MPS was calculated using the validated, locked model for grade group ≥2 cancer that includes serum PSA, urinary PCA3, and urinary TMPRSS2:ERG. The associations of age and volume with biomarkers were assessed in multivariable regression models. The RESULTS AND LIMITATIONS: The study included 314 screened men without evidence of cancer. In multivariable models including age and volume, PCA3 score was significantly associated with age (

conclusionsIn a cohort of longitudinally screened men without evidence of cancer, we found that MPS demonstrated less variability with noncancer factors (age, prostate volume) than PSA did. These findings support the biology of these markers as more cancer-specific than PSA and highlight their promise in reducing the morbidity associated with PSA-based screening. PATIENT SUMMARY: In a group of men with no evidence of prostate cancer, we found that each of three urine-based markers of cancer-PCA3, T2:ERG, and the commercially available MyProstateScore test-showed less variability with noncancer factors (age and prostate volume) than serum PSA (prostate-specific antigen) did. These findings support their proposed use as noninvasive markers of prostate cancer that could improve the accuracy of early detection.

Indexed as

BiomarkersGenomicsProstate cancerProstate cancer screening

Identifiers

PMID34337531
PMCPMC8317796
OpenAlexW3164757998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.